|
|
|
|
|
| |
|
|
|
|
Knowledge Centre on Cancer: Tackling Cancer and other Non-communicable diseases (NCDs)
Issue 1, February 2024
|
|
|
|
|
|
|
|
|
Introduction
|
|
|
|
|
Editorial
|
|
|
|
We are thrilled to bring you this first edition of our EC Knowledge Centre on Cancer Newsletter!
It's brimming with the latest news, noteworthy achievements, and fresh updates on our ‘Cancer and other non-communicable diseases (NCDs) portfolio’ projects at the Joint Research Centre of the European Commission.
Our goal is to keep you informed, inspired, and excited about the progress we're making in the world of cancer.
See video
|
|
|
|
|
|
|
Ciarán Nicholl, Director, Health and Food Directorate, EC Joint Research Centre
|
|
|
|
|
|
|
|
|
|
Policy news
|
|
|
A tribute to John Ryan, a champion of better health for all
|
|
It is with a heavy heart that we write this first article for our newsletter. We, the team at the JRC, give tribute to our beloved colleague, ally, and friend, former DG SANTE Deputy Director General, John Ryan who recently passed away.
|
|
|
|
|
|
|
|
January was cervical cancer awareness month
|
|
One of the flagship initiatives of the Europe’s Beating Cancer Plan is to ‘Eliminate cancers caused by Human papillomavirus’. It is estimated that in 2022, over 28,000 cervical cancer cases were diagnosed in the EU27 and over 17,000 of women died from cervical cancer (ECIS 2022).
|
|
|
|
Did you know that from over 100 existing types of HPV viruses around 14 of them, classified as ‘high risk’, can cause cancer?
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
European Commission recommends new measures on vaccine-preventable cancers under Europe's Beating Cancer Plan
|
|
The Recommendation aims to support Member States in their efforts to prevent cancer through vaccination.
|
|
|
|
|
|
|
|
Answer to a written question - Measures to counter the carcinogenic effects of sunbeds - P-003238/2023(ASW)
|
|
Answer given by Ms Kyriakides on behalf of the European Commission (5.12.2023) Under the prevention pillar of the Europe’s Beating Cancer Plan, the Commission is supporting awareness raising actions on key cancer risk factors.
|
|
|
|
|
|
|
|
Answer to a written question – Forthcoming revision of recommendations on smoke-free environments - P-003001/2023(ASW)
|
|
Answer given by Ms Kyriakides on behalf of the European Commission (5.12.2023) The Commission proposal to revise the 2009 Council recommendation on smoke-free environments was announced in Europe’s Beating Cancer Plan.
|
|
|
|
|
|
|
|
On 13th December 2023 Sub-Committee of Public Health Report on non-communicable diseases (NCDs) was adopted with 578 votes in favour, 39 against and 15 abstentions
|
|
Non-communicable diseases (NCDs) are diseases that are not passed from person to person; NCDs cause 90 % of all deaths in the EU, account for 80 % of the health burden in EU countries and their prevalence continues to grow across the EU.
|
|
|
|
|
|
|
Science News and Publications
|
|
|
Beating Cancer Inequalities in the EU: Spotlight on cancer prevention and early detection
|
|
This report prepared by the OECD will accompany the European Cancer Inequalities Registry (ECIR) Data Tool and the Country Cancer Profiles. It examines policies and actions to tackle cancer across Europe. Check out the analytical report.
|
|
|
|
|
|
|
|
|
|
|
|
European Cancer Inequalities Registry launched a childhood cancer topic and factsheet on childhood and adolescents cancer inequalities
|
|
Cancer is the most common cause of death due to disease in children and adolescents. It is estimated that 14 000 children and adolescents (0-14 years old) were diagnosed with cancer in Europe in 2022, and 2 000 a year die from cancer.
|
|
|
|
|
|
|
|
European Cancer Inequalities Registry published two new dimensions on the data tool: disability and employment status
|
|
ECIR is a flagship initiative of the Europe’s Beating Cancer Plan. It aims to highlight disparities, gaps and inequalities between and within EU countries (EU27 plus Iceland and Norway).
|
|
|
|
|
|
|
|
|
|
|
|
European Commission Initiative on Colorectal Cancer (ECICC) released the first recommendation on colorectal cancer screening ages
|
|
As well as the first good practice statements on healthy lifestyle.
|
|
|
|
For asymptomatic adults aged 50-69 with an average risk of colorectal cancer, the ECICC working group recommends screening for colorectal cancer in the context of an organised population-based screening programme.
|
|
|
|
|
|
|
|
|
|
|
Explore Food and Beverages Labels Explorer (FABLE)
|
|
High intakes of salt, sugars, total and saturated fats have been linked with higher prevalence of various non-communicable diseases; their intake in adults across Europe is above recommended levels.
|
|
|
|
|
|
|
|
Comparison of four Faecal Immunochemical Tests (FIT)
|
|
Faecal immunochemical (FIT) tests can detect very small amounts of human blood in stool. Colorectal cancer screening programs around the world use FIT tests, as they are non-invasive and inexpensive. The quantitative FIT tests provide a numerical result and this result is considered positive when the value is above a certain threshold. Various FIT tests are available on the market and these tests might not give comparable numerical results.
|
|
|
|
|
|
|
|
Radioligand therapy for advanced prostate cancer patients – are health care systems prepared?
|
|
The radiopharmaceutical 177Lu-PSMA-617, labelled with the beta-particle emitter 177Lu (lutetium), obtained marketing authorisation in the EU for the treatment of metastatic castration resistant prostate cancer in December 2022.
|
|
|
|
|
|
|
|
|
|
|
|
European Cancer Information System (ECIS) published 2022 estimates
|
|
The 2022 cancer mortality and incidence estimates and estimation of impact of population ageing on the burden of cancer up to 2040, are accompanied by factsheet series for total and individual cancers.
|
|
|
|
Did you know that breast, colorectal, cervical, prostate, lung and gastric cancers accounted for 54.2% of all new cancer cases and 50.2% of cancer deaths in the EU in 2022?
|
|
|
|
|
|
|
|
|
|
|
|
Congratulations to our colleagues that published excellent papers!
|
|
|
Two scientific articles:
Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study...
Complete cancer prevalence in Europe in 2020 by disease duration and country (EUROCARE-6): a population-based...
|
|
|
|
JRC Workshops on nuclear medical applications
|
|
|
Throughout 2023, the JRC has held a series of workshops on nuclear medical applications with the intent to gather stakeholders and bridge the gap between technological advances in the medical applications of radionuclides and the clinical options accessible to European patients.
|
|
|
|
|
Visit the European Rare Disease Registry Infrastructure (ERDRI)
|
|
|
ERDRI is part of the EU Platform on Rare Disease Registration (EU RD Platform) that copes with the fragmentation of rare disease patients' data contained in hundreds of registries across Europe.
|
|
|
|
Breast Cancer Prevention brief published in the Health Promotion and Disease Prevention Knowledge Gateway
|
|
|
According to the European Cancer Information System, it is estimated that breast cancer accounts for 13.8% of all new cancer cases diagnosed in the EU in 2022, which makes it the most frequently occurring cancer.
|
|
|
|
|
European Cancer Information System (ECIS) launched the new section on cancer prevalence
|
|
|
In 2020, 5% of the resident population in European countries was estimated to have had a cancer diagnosis in their lifetime. The new section presents estimates for 2020 by country, as one of the outcomes of the EUROCARE-6 study.
What's cancer prevalence? It considers everyone diagnosed, regardless of treatment status or time since diagnosis.
|
|
|
|
Check out our new Cancer Media News Report
|
|
|
The News report presents the latest scientific advancements in the area of cancer and other NCDs.
|
|
|
|
|
|
|
|
|
|
|
Open calls for funding
|
|
|
Call for tender: Study on the quality of life of cancer patients and survivors
|
|
|
|
|
|
|
|
|
Recently started EC-funded projects
|
|
|
|
|
Upcoming events
|
|
|
Belgian EU Presidency Workshop: Securing Access to Radiopharmaceuticals for all European Patients
|
|
|
|
|
|
|
|
|
|
14th European Breast Cancer Conference (EBCC 14), Milan, Italy
|
|
|
|
|
|
date |
|
20/03/2024 - 22/03/2024
|
|
|
|
|
|
|
Vacancies
|
|
|
FGIV - Scientist - Nuclear Physicist
|
|
|
|
|
|
|
|
|
|
FGIV - Scientist – Advanced Therapeutics, Regulatory Science, Health (PANGOLIN)
|
|
|
|
|
|
|
|
|
|
FGIV - Scientist – Advanced Therapeutics, Regulatory Science, Health (TARGET-RNA)
|
|
|
|
|
|
|
|
|
|
Vice-chair for the guidelines development working group of the European Commission Initiative on Breast Cancer
|
|
|
|
|
|
|
|
|
|
Working Group members for the European Commission Initiative on Colorectal Cancer
|
|
|
|
|
|
|
|
|
|
FGIV - Project Officer – Guideline activities on cancer screening
|
|
|
|
|
|
|
|
|
|
FGIV - Project Officer – Quality assurance activities on cancer
|
|
|
|
|
|
|
|
|
|
FGIV - Programme Officer - Science for policy officer -Guideline activities on cancer screening
|
|
|
|
|
|
|
|
|
|
FGIV Project Officer - Science for Policy Researcher - Healthcare quality activities on cancer
|
|
|
|
|
|
|
|
This is an edition of the enewsletter published by the Knowledge Centre on Cancer via the European Commission's Knowledge4Policy platform.
Subscribe, if this email was forwarded to you | You can unsubscribe on your profile page.
Luxembourg: Publications Office of the European Union, 2024
© European Union, 2024
The contents of the newsletter do not reflect the position or opinion of the European Commission. The Commission accepts no responsibility or liability whatsoever with regard to the information on this newsletter.
|
The European Commission is committed to personal data protection. Any personal data is processed in line with the Regulation (EU) 2018/1725. Please read the privacy statement.
|
|
ISSN: 2812-0493
|
Catalogue Number: KJ-CH-24-001-EN-N
|
|
 |
|
